Ruxolitinib = JACK 1/2 inhibitor. The IL-6/JAK/STAT3 implicated in the survival of cancer stem like cells. Inhibition of this axis may improve the activity of chemotherapy.
SO... "dispositioned to neoadjuvant chemotherapy" seems really weird to say. These volunteers were recommended to NACT.
NRG007 study schema: 
Who enrolled:
90.5% White
4.8% Black
4.8% race unknown
"patients who were BRCA mutated" should be restated as it's not a verb... "people with a documented BRCA mutation"
90.5% White
4.8% Black
4.8% race unknown
"patients who were BRCA mutated" should be restated as it's not a verb... "people with a documented BRCA mutation"
The slides on line for NRG-007 do not seem to coincide with what is being seen in the broadcast... There were 5 fatal toxicities (grade 5): 2 were in carbo/taxol treated and 3 in carbo/taxol/ruxolitinib....
Progression Free Survival was not statistically significantly changed. Overall survival not different.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
